Fundraising FoxMcurextx
2 known investors
Find your way into Mcurextx
Sign up to see every warm intro you have to Mcurextx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mcurextx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
mCureX Therapeutics is a South Korean pre-clinical biotech developing next-generation mRNA therapeutics and vaccines.
Also known as mCureX · mCureX Therapeutics
Investors · 2
Company profile
researched Aug 2026mCureX Therapeutics is a biotechnology company based in Seongnam, Gyeonggi Province, South Korea, that develops next-generation mRNA therapeutics and vaccines. Its work spans genetic diseases, infectious diseases and cancer, and its gene editing activity centers on CRISPR-Cas9 delivered via mRNA. The company is a subsidiary of OliX Therapeutics.
The company is at the pre-clinical stage and maintains a published R&D pipeline. It is privately funded.
Latest developments
In 2022 the company announced a collaboration with ToolGen to advance mRNA-based CRISPR-Cas9 gene editing for genetic eye diseases.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned as a pre-clinical mRNA therapeutics developer and a subsidiary of OliX Therapeutics, working in genetic disease, infectious disease and oncology indications.
Technology
The company's platform is built around next-generation mRNA therapeutics and vaccines, including mRNA-based delivery of CRISPR-Cas9 genome editing components.
Go-to-market
Patients with genetic diseases, infectious diseases and cancer, addressed through therapeutic and vaccine programs.
Geography
Headquartered in Seongnam, Gyeonggi, South Korea.
History
The company operates as a subsidiary of OliX Therapeutics. Sangwook Lee, previously a researcher in the Ota Lab until 2024, serves as Chief Technology Officer.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsmCureX Therapeutics announced a collaboration with ToolGen to advance mRNA-based CRISPR-Cas9 gene editing for the treatment of genetic eye diseases.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 3
primary sources listed
- Company: mCureX Therapeuticscrisprmedicinenews.com · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Mcurextx do?
- mCureX Therapeutics is a South Korean pre-clinical biotech developing next-generation mRNA therapeutics and vaccines.
- Who are Mcurextx's investors?
- Mcurextx's investors include Aju IB Investment, Kiwoom Investment.